TSHA — Taysha Gene Therapies Balance Sheet
0.000.00%
Last trade - 00:00
- $607.81m
- $504.73m
- $15.45m
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | PROSPECTUS | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Cash and Equivalents | |||||
Cash and Short Term Investments | — | 251 | 149 | 87.9 | 144 |
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 0.015 | 258 | 160 | 96.4 | 150 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | — | 0.287 | 50.6 | 25.9 | 20.4 |
Other Long Term Assets | |||||
Total Assets | 0.015 | 259 | 214 | 126 | 173 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 0.15 | 7.13 | 51.7 | 62.8 | 36.8 |
Long Term Debt | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Total Other Liabilities | |||||
Total Liabilities | 0.15 | 7.58 | 119 | 125 | 97.8 |
Redeemable Preferred Stock | |||||
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Other Equity | |||||
Total Equity | -0.135 | 251 | 95.4 | 0.949 | 74.9 |
Total Liabilities & Shareholders' Equity | 0.015 | 259 | 214 | 126 | 173 |
Total Common Shares Outstanding |